Psychedelic Stocks

2020-10-20 Jeff Nielson

Psychedelic drug stocks may represent the best investing strategy to hedge against COVID-19 economic risks.

2020-10-20 PSW Editor

Revive has signed a psychedelics supply agreement with HAVN Life Sciences.

2020-10-20 PSW Editor

Pharmather is seeking to advance a ketamine-based therapy for the treatment of Parkinson's disease.

2020-10-16 PSW Editor

Mydecine begins the dual listing process to obtain an LSE listing.

2020-10-15 Jeff Nielson

Acute need. Huge markets. A wide-open playing field. Those are some of the best reasons to invest in psychedelic drug stocks.

2020-10-15 PSW Editor

Mind Cure brings in an expert in fintech to be its new CTO.

2020-10-14 Jeff Nielson

Both Numinus and Mydecine have been rising recently on big volume. Which is the better bet?

2020-10-14 PSW Editor

Numinus rolls out the list of Advisors on its psychedelics Advisory Council

2020-10-14 PSW Editor

Primo Nutraceuticals is commencing preliminary psychedelics research in a partnership with Mecan Biotech.

2020-10-14 PSW Editor

Field Trip's new strategic partnership will facilitate bringing its ketamine-assisted psychotherapy for PTSD to military veterans.

2020-10-13 PSW Editor

Mind Cure adds an expert in neuroscience and nutrition to its Advisory Board.

2020-10-13 PSW Editor

The newest psychedelics company plans to focus on both ketamine- and psilocybin-assisted psychedelics R&D.